1. Do oral corticosteroids reduce the severity of acute lower respiratory tract illnesses in preschool children with recurrent wheezing? 
Avraham Beigelman, MD, MSCI, Tonya S. King, PhD, David Mauger, PhD, Robert S. Zeiger, MD, PhD, Robert C. Strunk, MD, H. William Kelly, PharmD, Fernando D. Martinez, MD, Robert F. Lemanske, MD, Katherine Rivera-Spoljaric, MD, MSCI, Daniel J. Jackson, MD, Theresa Guilbert, MD, Ronina Covar, MD, Leonard B. Bacharier, MD 
Journal of Allergy and Clinical Immunology 
Volume 131, Issue 6, Pages e14 (June 2013)
DOI: /j.jaci
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Comparison of total symptom scores in the AIMS cohort between episodes that were or were not treated with OCSs (corresponding to the comparison detailed in Table IV, without adjustment for propensity score). Figures of the secondary outcomes are available in this article's Online Repository. Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Comparison of total symptoms scores in the MIST cohort between episodes that were or were not treated with OCSs (corresponding to the comparison detailed in Table V, without adjustment to maximal propensity). Figures of the secondary outcomes are available in this article's Online Repository. Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig E1
Comparisons of symptom scores in the AIMS cohort between episodes that were or were not treated with OCSs (corresponding to the comparisons detailed in Table IV, without adjustment for propensity score). Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Fig E1
Comparisons of symptom scores in the AIMS cohort between episodes that were or were not treated with OCSs (corresponding to the comparisons detailed in Table IV, without adjustment for propensity score). Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6. Fig E2
Comparisons of symptom scores in the MIST cohort between episodes that were or were not treated with OCSs (corresponding to the comparisons detailed in Table V, without adjustment to maximal propensity). Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7. Fig E2
Comparisons of symptom scores in the MIST cohort between episodes that were or were not treated with OCSs (corresponding to the comparisons detailed in Table V, without adjustment to maximal propensity). Data are stratified based on episodes that met and did not meet severity criteria.
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8. Fig E3
Survival curves describing the proportion of episodes in which return to baseline respiratory symptoms was achieved among episodes that were or were not treated with OCSs. The baseline symptom level was defined as the mean of daily symptoms between days 14 and 7 before the beginning of the episode (ie, days −7 to −14).
Journal of Allergy and Clinical Immunology  , e14DOI: ( /j.jaci )
Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions